RYTM news

The US-based snack maker modified its trademark licensing agreement to allow the IP owner to sell serviceables outside regulated channels. The financial impact includes a lowered carve-out fee for 2026. The deal is subject to a broad non-competition and non-solicitation covenant.

Rhythm Pharmaceuticals reports second-quarter net product revenue of $71.3 million, up 19% sequentially, following the successful U.S. launch of IMCIVREE for acquired hypothalamic obesity. The company attributed the performance to increased demand for the treatment.